3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Nasopharyngeal Carcinoma
3
Melanoma
3
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vascular Complications
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Mouth Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Immune-Related Adverse Events
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Cancer Metastatic
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
palbociclib
1
nilotinib
1
isatuximab
1
avelumab
1
atezolizumab
1
acalabrutinib
1
Whole-Body Irradiation
1
Trastuzumab
1
Sirolimus
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Immune Checkpoint Inhibitors
×
90 days
×
Clear all
No trials found.